- Innate Pharma SA’s (NASDAQ:IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ:AZN) did not meet a pre-defined threshold for efficacy.
- Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.
- There were no new safety findings. AstraZeneca plans to share the data in due course.
- Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity.
- The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
- Monalizumab is being studied in a Phase 3 study sponsored by AstraZeneca, evaluating durvalumab in combination with monalizumab or AstraZeneca’s oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer.
- Price Action: IPHA shares are down 16.3% at $2.68 during the premarket session on the last check Monday.
Cathie Wood Gets Elon Musk’s Nod After Slamming Regulatory Failure Over Banking Crisis: ‘Lot Of … Similarities To 1929’
ARK Investment Management CEO Cathie Wood believes regulators should have focussed on the opaque failure points of the traditional banking system rather than blocking decentralized financial platforms “th
